Edition:
India

Shilpa Medicare Gets 483 Observations From U.S. FDA For SEZ Formulation Facilities In Telangana


Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Shilpa Medicare Ltd ::SAYS GOT 483 OBSERVATIONS FROM U.S. FDA IN RELATION TO SEZ FORMULATION FACILITIES SITUATED AT JADCHERLA, TELANGANA.SAYS TOTAL 10 OBSERVATIONS WERE CITED DURING CLOSE UP MEETING.SAYS 7 OBSERVATIONS ARE IMPROVEMENT IN PROCEDURES AND PRACTICES.SAYS 3 OBSERVATIONS RELATED TO SETTING OF ANALYTICAL SPECIFICATIONS, TEST PROCEDURES, METHOD VALIDATION. 

Related Company News

Company Quote

252.6
-8.25 -3.16%
3:29pm IST